Accordingly, the ability to capture the mutational status of RCC-relevant genes, including VHL, BAP1 and PBRM1, is critical for the clinical utility of liquid biopsy analysis in RCC, as the presence of somatic mutations in these particular genes alone or in combination with each other are indicative of distinct disease outcomes [35]. The gene discussed is PBRM1; the disease is renal cell adenocarcinoma.